Description
Springer Oncoimmunology A Practical Guide for Cancer Immunotherapy 1st Editon 2019 Softbound by Laurence Zitvogel, Guido Kroemer
In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. Fundamental bases: Immunology for the non immunologist: Cellular and molecular bases of cancer immunosurveillance.- Innate immunity/NK in cancer immunosurveillance.- Biology of regulatory T cells.- Adenosine, P2R receptors.-Plasmacytoid DC dysfunctions in cancer.- Chemotherapy and MDSC.- Biology of Myeloid Derived Suppressor Cells.- T cell fitness/polarization for antitumor immune responses.- Tumor associated antigens and neoantigens.- Tumor associated antigens and neoantigens.- Immunization with peptides.- Immunogenic cell death and chemotherapy.- Breakthrough or advanced status of approaches: Cancer vaccines in HPV malignancies.- Innate sensing of tumors and TLR agonists.- DC-based cancer vaccines in melanoma.- DC-based vaccines in breast cancer.- T cell-based immunotherapies : CAR-T and TCR engineered T cells.-IDO and TDO-based inhibition in cancer. - FDA-EMA approval of I-O: Tumor-specific antibodies.- Anti-CTLA4 Abs.- Bispecific anti-CD3xCD19 antibodies.- Combination of ICB in MM.- Oncolytic viruses.- Bacillus Calmette-Guérin and mycobacterial cell wall nucleic acid complexes in the treatment of non-muscle-invasive bladder cancer .- The immunoscore.- PDL-1 and other immunological diagnosis tools.- Developping fields: The development of anti-41BB, Lag3, Anti-OX40, anti-ICOS, anti-GITR Ab.- mRNA-based vaccination.- Links between tumor genetics and immunotherapy.- Local immunotherapies of cancer.- Preventive DC-based cancer vaccines.- Gut microbiota/oncomicrobiotics in cancer therapeutics.- Strategies to reduce intratumoral Treg.- Cold versus hot tumors.- Immunopathology : an emerging field.- Changes in Clinical Practice: Side effects of I-O.- The clinical armamentarium in melanoma.- The clinical armamentarium in kidney cancers.- The clinical armamentarium in lung cancers.- The clinical armamentarium in prostate cancers.- Challenges of O-I for breast, ovarian, and non MSI colon cancers.- Challenges in colon cancers.- Current status of O-I in hematologic malignancies.- Glioma and I-O.- Assessing affinity and avidity of TCRs.- Immunomonitoring studies.